BFM
ANEB

Boothbay Fund Management’s Anebulo Pharmaceuticals ANEB Stock Holding History

Boothbay Fund Management’s Portfolio ANEB Stock Details ANEB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-18,836
Closed -$47.1K – 1946
2025
Q3 		$47.1K Hold
18,836
– – ﹤0.01% 1790
2025
Q2 		$27.1K Hold
18,836
– – ﹤0.01% 1384
2025
Q1 		$24.5K Hold
18,836
– – ﹤0.01% 1323
2024
Q4 		$31.6K Sell
18,836
-142
-0.7% -$234 ﹤0.01% 1402
2024
Q3 		$36.6K Hold
18,978
– – ﹤0.01% 1528
2024
Q2 		$51.8K Hold
18,978
– – ﹤0.01% 1409
2024
Q1 		$54.5K Hold
18,978
– – ﹤0.01% 1466
2023
Q4 		$45.9K Hold
18,978
– – ﹤0.01% 1534
2023
Q3 		$58K Buy
18,978
+1,659
+10% +$4.6K ﹤0.01% 1620
2023
Q2 		$40.7K Hold
17,319
– – ﹤0.01% 1686
2023
Q1 		$50.2K Hold
17,319
– – ﹤0.01% 2020
2022
Q4 		$42K Hold
17,319
– – ﹤0.01% 1889
2022
Q3 		$48K Sell
17,319
-14
-0.1% -$50 ﹤0.01% 2119
2022
Q2 		$90K Hold
17,333
– – ﹤0.01% 2002
2022
Q1 		$123K Hold
17,333
– – ﹤0.01% 2053
2021
Q4 		$110K Hold
17,333
– – ﹤0.01% 1693
2021
Q3 		$114K Sell
17,333
-2,502
-13% -$17.5K ﹤0.01% 1777
2021
Q2 		$135K Buy
+19,835
New +$148K ﹤0.01% 1674

Other funds holding ANEB

2L
22NW LP Seattle, Washington $146M AUM 29.83% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
RC
Rangeley Capital New Canaan, Connecticut $103M AUM 77.32% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Boothbay Fund Management's ANEB Position: Q4 2025 in Review

Boothbay Fund Management sold out of Anebulo Pharmaceuticals (ANEB) in Q4 2025, closing a stake of 18,836 shares — an estimated $47.1K sold.

Boothbay Fund Management first reported a position in ANEB in Q2 2021 and held it in 18 quarters. The position peaked at $135K in Q2 2021. 19 funds tracked by Wall St. Rank hold ANEB as of Q4 2025.

  • Boothbay Fund Management reported no remaining Anebulo Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Boothbay Fund Management sold 18,836 Anebulo Pharmaceuticals shares in Q4 2025, an estimated $47.1K.
  • Boothbay Fund Management first reported a position in Anebulo Pharmaceuticals in Q2 2021 and held it in 18 quarters.
  • Boothbay Fund Management's Anebulo Pharmaceuticals position peaked at $135K in Q2 2021.
  • 19 funds tracked by Wall St. Rank held Anebulo Pharmaceuticals as of Q4 2025.

Based on Boothbay Fund Management's 13F filing for Q4 2025, filed 17 Feb 2026.